LNSRHealthcare · Medical DevicesThe 3 Wall Street analysts covering LENSAR, Inc. hold a median 12-month price target of $11 — +70.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores LENSAR, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LNSR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +70.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Sept 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $11 |
| 20 Aug 2026 | BTIG | Maintains | Buy | $9.00 → $10 |
| 20 Aug 2026 | BTIG | Maintains | Buy | — |
| 13 Aug 2026 | BTIG | Maintains | Buy | $7.00 → $9.00 |
| 13 Aug 2026 | BTIG | Maintains | Buy | — |
| 18 Mar 2026 | BTIG | Upgrade | Buy | $10 |
| 18 Mar 2026 | BTIG | Upgrade | Buy | — |
| 24 Mar 2025 | Lake Street | Downgrade | Hold | — |
| 28 Feb 2025 | Lake Street | Maintains | Buy | — |
| 19 Mar 2024 | Lake Street | Initiates | Buy | — |
| 22 Nov 2021 | BTIG | Initiates | Buy | — |
| 24 Feb 2021 | SVB Leerink | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNSR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, LENSAR, Inc. returned −47.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 62% of US stocks
Cheaper than 18% of US stocks
Cheaper than 80% of US stocks
Higher than 67% of US stocks
Higher than 73% of US stocks
Higher than 69% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LENSAR, Inc. has a market value of $82.3M and an enterprise value of $84.9M.
Revenue in the twelve months to 30 June 2026: $60.3M. The latest quarter grew 18.4% year on year.
Net income over the same four quarters: $34.7M, a 57.6% net margin.
Diluted earnings per share, trailing twelve months: $−0.33.
Free cash flow in the twelve months to 30 June 2026: −$7.3M.
Trailing P/E: 37.2×; forward P/E: −13.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
LENSAR, Inc. employs 150 people — $402K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LENSAR, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cedar Grove Capital’s Q3 2026 update said it closed long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life, and closed short positions in several other companies. It also initiated a small tracking position in Zedcor while continuing due diligence.
Why it matters — The excerpt does not mention LENSAR or LNSR, so it provides no direct company-specific update for LNSR watchers.
LENSAR reported 18% revenue growth for the second quarter of 2026, continuing its commercial rebuilding efforts after the termination of its proposed merger with Alcon near the end of the first quarter.
Why it matters — A LNSR watcher would care because the company is demonstrating revenue growth and recovering commercial momentum after a major deal fell through earlier this year.
Seeking Alpha published the transcript of LENSAR, Inc.'s Q2 2026 earnings call. The item is the full transcript of the company's quarterly earnings discussion.
Why it matters — A LENSAR watcher would want to review the earnings call transcript for the company's Q2 2026 financial details and management commentary.
LENSAR reported its second quarter 2026 financial results and provided a business update. The company recorded 10 ALLY Robotic Cataract Laser System placements in the quarter, with a backlog of 13 ALLY systems as of June 30, 2026, and second-quarter recurring revenue of $13.7 million. Its total installed base rose to 445 systems, supported by a 30% increase in ALLY placements.
Why it matters — LENSAR watchers would care because the results show growth in ALLY system placements, a rising installed base, and higher recurring revenue, all of which reflect the company's commercial momentum.
The 3 Wall Street analysts covering LENSAR, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering LENSAR, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENSAR, Inc. 62 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, LENSAR, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +70.5% from the last close, and Ticker Nerd's factor model ranks LENSAR, Inc. 62 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LENSAR, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNSR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.
LENSAR, Inc. returned -47.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management.
The most recent item we track (Seeking Alpha, 7 Oct 2026): "Cedar Grove Capital Q3 2026 Portfolio Update". Cedar Grove Capital’s Q3 2026 update said it closed long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life, and closed short positions in several other companies. It also initiated a small tracking position in Zedcor while continuing due diligence.
LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management. Its current portfolio centers on the LENSAR Laser System and the ALLY Robotic Cataract Laser System, which combine imaging, planning, and laser-based treatment tools to support surgeons in refractive cataract procedures. The company’s systems are used to help manage key steps of surgery, including treatment planning, precision delivery, and workflow efficiency in clinical settings. LENSAR also provides related consumables, procedure licenses, training, installation, and maintenance services, making its offerings part of a broader surgical platform rather than standalone hardware. Headquartered in Orlando, Florida, LENSAR serves ophthalmic practices and surgical centers in the United States and international markets.
CEO Mr. Nicholas T. Curtis · 150 employees · United States · https://www.lensar.com
